Skip to content
PeptideAI
In vitro onlyskinlongevity

Hexapeptide-11

A yeast-fermentation-derived hexapeptide marketed as an anti-senescence active for dermal firmness rather than as a wrinkle-specific ingredient.

Also known as Peptamide 6, yeast-derived hexapeptide-11, Phe-Val-Ala-Pro-Phe-Pro, Peptamide 6

In vitro only — Cell or tissue studies. A mechanism, not yet an effect in a living body.

Gene-expression data in cultured keratinocytes and fibroblasts from the supplier is the entirety of the case. No independent human trial exists, and 'anti-senescence' here means altered gene expression, not demonstrated senescent-cell clearance.

How it works

Hexapeptide-11 was originally isolated from low-molecular-weight fractions of Saccharomyces cerevisiae fermentation lysate and is now made synthetically for cosmetic-grade purity. Supplier gene-array work reports downregulation of senescence- and apoptosis-associated genes in both keratinocytes and dermal fibroblasts, with corresponding increases in collagen and elastin production and improved epidermal turnover. The pitch is anti-senescence rather than matrikine signalling, which places it alongside the small but growing group of cosmetic actives borrowing language from longevity biology. No receptor or defined pathway has been published, and the senescence claims rest on expression data rather than on measured senescent-cell burden in human skin.

Targets: Senescence-associated gene expression, Dermal fibroblasts, Keratinocyte turnover, Collagen and elastin synthesis

Dosing

ProtocolDoseFrequencyRoute
Standard leave-on serumNo timing constraints.—once or twice dailytopical
  • · Products typically contain 0.01-1% w/w. Most formulations sit at the low end of that range; there is no dose-response data to justify pushing higher.

Cycling

Continuous daily use.

Work out your exact syringe units →

Pharmacology

Half-life
Not established.
Onset
8-12 weeks of daily use.
Routes
topical
Molecule
Synthetic hexapeptide (originally yeast-derived)
Sequence length
6 amino acids
Molecular weight
676.8 Da

Handling

Diluent
Distilled or deionised water with a glycol fraction
Typical mix
20 or 50 mL
Vial sizes
50, 100, 200 mg
Lyophilised
Sealed, cool and dry; freezer for long-term.
Reconstituted
Refrigerated and preserved.

Mixing

Two phenylalanines and two prolines make it only moderately water soluble; a glycol helps.

Side effects

  • rareIrritation

Combining it

  • synergymatrixyl-3000 — Different rationales for the same fibroblast output; commonly co-formulated.
  • synergyprogeline — Both are pitched at cellular ageing rather than surface wrinkles.

What to monitor

  • · Standardised photography at 0 and 12 weeks.

Legal status

Cosmetic ingredient (INCI Hexapeptide-11) approved worldwide.

References

  • Arch Personal Care / Lonza Peptamide 6 technical dossier (other)

Mechanism in depth

This is the one niche compound in the class with a genuinely independent academic paper behind it, and the paper says something more specific than the marketing does. Sklirou and colleagues in Trougakos's lab at Athens studied hexapeptide-11 in human diploid fibroblasts and characterised it as a modulator of the proteostasis network — the integrated system of chaperones, the ubiquitin-proteasome system and autophagy that keeps the cellular proteome from accumulating damaged and aggregated protein. That is a meaningfully different and better claim than the vague anti-senescence framing on product pages. Proteostasis collapse is one of the recognised hallmarks of ageing, and proteasome activity specifically declines in senescent fibroblasts and in aged human skin. A compound that supports proteasome function in dermal fibroblasts has a coherent mechanistic story for why collagen and elastin output might improve, because a fibroblast spending its capacity on degrading damaged protein is not a fibroblast building matrix. Gruber's earlier work in the Journal of Cosmetic Science looked at modulation of cellular senescence in fibroblasts and dermal papilla cells, which is the supplier-side companion result. What remains unestablished is the step from a fibroblast in a dish to a face. There is no independent human trial, and the supplier's anti-senescence language means altered gene expression, not measured senescent cell clearance in skin — those are very different things, and the difference matters because the senolytics field has spent a decade learning it.

What usually goes wrong

Overreading the word senescence. In the cosmetic marketing it means gene expression changed in a cell culture. In the ageing biology literature it means a specific, stable cell-cycle-arrested state with a defined secretory phenotype, and clearing those cells is what senolytics attempt. Hexapeptide-11 has not been shown to clear senescent cells from human skin and nobody has claimed the measurement. Second, the concentration range of 0.01-1% quoted for products is enormously wide and there is no dose-response data anywhere in it, so nobody including the manufacturer knows what the right level is. Third, expecting a wrinkle result — this is pitched at firmness and cellular ageing, and if you want lines to change you want a retinoid.

Pharmacokinetics

Crosses blood-brain barrier
no
Metabolism
Unprotected termini, so exopeptidase attack is available. The two prolines confer some conformational rigidity and proline-adjacent bonds resist many peptidases, which may partly compensate.
Elimination
No meaningful systemic exposure.

Receptor targets

  • Proteostasis network — proteasome activity and chaperone expression in human diploid fibroblasts — No receptor identified; characterised functionally by Sklirou and colleagues

    Modulation of the protein quality control machinery, which is the best-characterised effect of this peptide.

  • Senescence-associated gene expression — Transcriptional

    Downregulation of senescence- and apoptosis-associated genes in keratinocytes and fibroblasts, with claimed increases in collagen and elastin output.

What to expect, and when

Week 8-12 for anything visible, with week 12-16 as the honest assessment point. Because the claimed mechanism is cellular capacity rather than direct matrix signalling, the effect should be slow and cumulative, and there is no human data describing its actual time course.

Stacking and comparisons

No chemical incompatibilities. Commonly co-formulated with matrikines like Matrixyl 3000, and the pairing is logically complementary rather than redundant: one supplies a build signal and this one, if the proteostasis story holds, improves the cell's capacity to act on it. Progeline is the other common partner, both being pitched at cellular ageing rather than surface wrinkles. If you are building a routine around the longevity-biology framing, the honest ranking is that a retinoid has orders of magnitude more evidence for reversing measurable features of skin ageing than any anti-senescence peptide, and sunscreen prevents more of the damage than anything reverses.

Against the rest of the niche cosmetic peptides, hexapeptide-11 is unusual in having an independent, mechanistically specific academic paper from a proteostasis lab. That does not make it clinically proven — there is still no human trial — but it means the mechanism is a real finding rather than a supplier assertion, which cannot be said for Vialox, Syn-Coll or Melanostatine. Against Progeline, both target cellular ageing and this one has the better paper. Against a retinoid or sunscreen, no contest on evidence.

Rough cost

$12–$65/month. Raw hexapeptide-11 runs roughly $40-100 per gram. Finished products $15-65 a month. Market observation, not a sourced pricing study.

Genuinely uncertain

  • No independent human trial exists. The evidence is fibroblast and keratinocyte culture.
  • Anti-senescence here means altered gene expression, not demonstrated senescent cell clearance in human skin.
  • No permeation data exist.
  • The sequence Phe-Val-Ala-Pro-Phe-Pro is consistently reported for INCI Hexapeptide-11 but I could not confirm it against a primary source.
  • The molecular weight of 676.8 Da in the Core record is unconfirmed against a primary source.
  • The 0.01-1% use range spans two orders of magnitude with no dose-response data to narrow it.

Papers